Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, Y and W-135 conjugate vaccine
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Group ACYW135 Meningococcal Conjugate Vaccine (MCV4) developed by Ningbo Rong'an Biological Pharmaceutical (a subsidiary of AIM Vaccine) is a quadrivalent vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. Unlike traditional polysaccharide vaccines, this conjugate vaccine chemically links the capsular polysaccharides of the four serogroups to a carrier protein. This conjugation technology converts the T-cell independent polysaccharides into T-cell dependent antigens, which induces a more robust immune response, particularly in infants and young children, and promotes long-term immunological memory. The vaccine is administered via intramuscular injection and has received regulatory approval in China.
- Other names
- Group ACYW135 meningococcal conjugate vaccineACYW135 meningococcal conjugate vaccineACYW-135 meningococcal conjugate vaccineACYW 135 meningococcal conjugate vaccineQuadrivalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, Y and W-135 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, Y and W-135 conjugate vaccine.